Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN Poll

 More »
Dec 15, 2011

Second-Opinion Genetic Testing

Do you believe the U.S. can develop a system to protect innovator diagnostic firms but also safeguard those offering confirming tests against patent infringement?

Yes
 
  57.1%
No
 
  0.0%
Undecided
 
  42.9%

Suggest a Poll
More Polls » View Results »

In mid-January, the U.S. Patent & Trademark Office (USPTO) is expected to announce dates and places for hearings on confirming genetic diagnostic tests. USPTO faces a June 16 deadline for submitting to Congress a study on “effective ways to provide independent, confirming genetic diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic tests exist.” Advocates for such testing say the current system based on patent eligibility drives up costs, limits patient options, reduces innovation, and harms medical practice. Developers of diagnostics, however, say patent eligibility provides the financial incentives that allow them to recoup the costs of developing the tests. Where does the truth lie?

Related Content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll